Latent TB Infection Testing Market

The main ways to diagnose LTBI are by placing a tuberculin skin test (TST) on the forearm or by getting a TB blood test, in addition to obtaining a chest radiograph (x-ray) if either one of these tests is positive. One-third of the world's population has LTBI. The TB germs are dormant (asleep) in the body.
Latent TB Infection Testing Market contains market size and forecasts of Latent TB Infection Testing in Global, including the following market information:
Global Latent TB Infection Testing Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Latent TB Infection Testing market was valued at 1436.4 million in 2021 and is projected to reach US$ 2029.6 million by 2028, at a CAGR of 5.1% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Mantoux Test / Tuberculin Skin Test (TST) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Latent TB Infection Testing include Endo International plc (Par Sterile Products, LLC/JHP Pharmaceuticals, LLC), Pharmstandard (Generium Pharmaceutical), Sanofi S.A./Sanofi Pasteur Ltd., Statens Serum Institut (SSI), Autoimmun Diagnostika (AID) GmbH, Beijing Wantai Biological Pharmacy Enterprise Co. Ltd., Haikou VTI Biological Institute (Vaccine Technologies, Inc.), Immunoshop India Pvt. Ltd. and Qiagen N.V., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Latent TB Infection Testing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Latent TB Infection Testing Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Latent TB Infection Testing Market Segment Percentages, by Type, 2021 (%)
Mantoux Test / Tuberculin Skin Test (TST)
Interferon-Gamma Release Assay (IGRA)
Global Latent TB Infection Testing Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Latent TB Infection Testing Market Segment Percentages, by Application, 2021 (%)
Hospitals
Public and Student Health
Physician Offices and Clinics
Others (Military, Correctional Facilities, Chronic Care Homes, and Others)
Global Latent TB Infection Testing Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Latent TB Infection Testing Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Latent TB Infection Testing revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Latent TB Infection Testing revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Endo International plc (Par Sterile Products, LLC/JHP Pharmaceuticals, LLC)
Pharmstandard (Generium Pharmaceutical)
Sanofi S.A./Sanofi Pasteur Ltd.
Statens Serum Institut (SSI)
Autoimmun Diagnostika (AID) GmbH
Beijing Wantai Biological Pharmacy Enterprise Co. Ltd.
Haikou VTI Biological Institute (Vaccine Technologies, Inc.)
Immunoshop India Pvt. Ltd.
Qiagen N.V.
Quest Diagnostics, Inc. (Oxford Immunotec Global plc)
SD Biosensor, Inc.